Clinical Trials - May 11, 2022
Targovax enters collaboration with Oslo University Hospital
Targovax has entered into a clinical trial collaboration agreement with Oslo University Hospital (OUS) to run a phase 1/2 study testing polyvalent mutant RAS vaccine TG01 in multiple myeloma (MM) following standard of care (SoC) therapy. Targovax was recently awarded two research grants from Innovation Norway and the Norwegian Research Council, totaling NOK 18m, to […]
Business article - March 21, 2022
Targovax proposes a drop-down demerger
The Board of Directors of Targovax has signed a joint demerger and merger plan, respectively, for the transfer of the operational activities of the company to its wholly-owned subsidiary, Targovax Solution AS. The transfer is proposed carried out as a “drop-down demerger” where the company demergers operations and assets to its subsidiary Athomstart Invest 586 […]
Collaboration - March 2, 2022
Targovax enters collaboration with Karolinska Institutet
Targovax has entered into a two-year research collaboration with Professor Michael Uhlin of the Department of Clinical Science, Intervention and Technology at Karolinska Institutet, to develop and characterize novel ONCOS oncolytic viruses. “Prof. Uhlin is a highly accomplished scientist with deep experience in translational and clinical immunology. His expertise and research capabilities will play a […]
Intellectual Property - January 17, 2022
Targovax granted new patents
Targovax has announced that patents no CN108495934 and JP6974350 have been granted by the Chinese and Japanese Patent Offices, respectively. The patents cover the use of ONCOS-102 in combination with chemotherapy in malignant mesothelioma. “We are delighted that these patents have been granted, further strengthening Targovax’s intellectual property portfolio. The 30-month data from our ONCOS-102 […]
Pharma Business - August 17, 2021
Targovax receives Fast Track designation
Targovax announced earlier this summer that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA. The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor […]
Clinical Trials - November 24, 2020
Targovax announces new results from its ONCOS-102 trial
Targovax has announced that the combination of ONCOS-102 and pembrolizumab (Keytruda) has demonstrated 35% best objective response rate (ORR) in anti-PD1 refractory malignant melanoma. In this two-part, open label phase 1 trial the combination of ONCOS-102 and the anti-PD1 checkpoint inhibitor (CPI) pembrolizumab has been tested in patients with advanced, unresectable melanoma who have had […]
